Accelerated Pharma Inc. (ACCP)

Access Pharmaceuticals Inc, formerly known as Chemex Corporation, was incorporated in 1974. The Company is an emerging biopharmaceutical company developing pharmaceutical products based upon its nanopolymer chemistry technologies and other drug delivery technologies. It currently has one marketed product licensed in the U.S. and China, and has products and platform technologies in various stages of development. MuGard, is the Company's marketed product for the management of oral mucositis, a frequent side-effect of cancer therapy for which there is no established treatment. MuGard, a nanopolymer formulation, has received marketing allowance in the U.S. from the FDA. The Company's partners in China have received an acceptance letter from the State Food and Drug Administration of the People's Republic of China, which provides marketing approval in China for MuGard. Further, the Company along with Hanmi Pharmaceutical Co. Ltd., is also marketing MuGard in South Korea. In addition to its product MuGard, the Company is working on products using its mucoadhesive hydrogel technology. CobOral is Company's preclinical nanopolymer oral drug delivery technology based on the natural vitamin B12 oral uptake mechanism. The Company has developed product candidates based upon the CobOral delivery technology. CobaCyte is a preclinical technology that makes use of the fact that cell surface receptors for vitamins such as B12 are often overexpressed by certain cells including many cancers. This technology uses nanopolymer constructs to deliver more anti-cancer drug to tumors while protecting normal tissues. The Company competes with EUSA Pharma, DARA BioSciences, Inc., Camurus AB, Biovitrum for the treatment of mucositis. Further, the Company may compete with other companies which are developing products to treat mucositis using the mucoadhesive liquid technology, as well as the oral drug delivery system, such as ActoGeniX N.V., Alder Biopharmaceuticals, Inc., Applied Protein Sciences, LLC, Avaxia Biologics, Inc, BioAlliance Pharma S.A., BMG Pharma s.r.l., Camurus AB, DARA BioSciences, Inc. EUSA Pharma, Galera Therapeutics, Inc. Maya Biotech Ltd. , NephRx, Piramal Healthcare Ltd., Bristol-Myers Squibb, Centocor, Endocyte, GlaxoSmithKline, among others. The Company is subject to extensive regulation by the federal government, mainly by the FDA, and, to a lesser extent, by other federal and state agencies as well as comparable agencies in foreign countries where registration of products will be pursued.